Article
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
European journal of cancer (Oxford, England : 1990) - 1 Jan 2023
Riedel Richard, Fassunke Jana, Tumbrink Hannah L, Scheel Andreas H, Heydt Carina, Hieggelke Lena, Scheffler Matthias, Heimsoeth Alena, Nogova Lucia, Michels Sebastian, Weber Jan-Phillip, Fischer Rieke N, Eisert Anna, Westphal Theresa, Schaufler Diana, Siemanowski Janna, Ihle Michaela A, Wagener-Ryczek Svenja, Castiglione Roberta, Pappesch Roberto, Rehker Jan, Jürgens Jessica, Stoelben Erich, Bunck Anne, Kobe Carsten, Merkelbach-Bruse Sabine, Sos Martin L, Büttner Reinhard, Wolf Jürgen
Abstract excerpt
OBJECTIVES: Resistance to MET inhibition occurs inevitably in MET-dependent non-small cell lung cancer and the underlying mechanisms are insufficiently understood. We describe resistance mechanisms in patients with MET exon 14 skipping mutation (METΔex14), MET amplification, and MET fusion and report treatment outcomes after switching therapy from type I to type II MET inhibitors. MATERIALS AND METHODS: Pre- and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.